Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2002, for Eli Lilly and Company, a pharmaceutical company headquartered in Indianapolis, Indiana. The company operates primarily in one significant business segment: pharmaceutical products for human use, with a non-material animal health segment. As of April 30, 2002, there were approximately 1.12 billion shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $2,561.1 million | $2,805.7 million |
| Net Income | $629.2 million | $806.8 million |
| Earnings Per Share (Diluted) | $0.58 | $0.74 |
| Gross Margin | 79.3% | 81.4% |
| Operating Cash Flow | $238.2 million | $527.6 million |
| Total Debt | $3.86 billion | $3.42 billion (approx. based on Q4 2001 + change) |
| Cash and Short-term Investments | $3.86 billion | $3.73 billion (Dec 31, 2001) |
Debt and Liquidity: Total debt increased by $437.1 million from December 31, 2001, primarily due to the issuance of $500 million in 6% 10-year notes in March 2002. Cash and cash equivalents totaled $2.88 billion, with short-term investments of $977.1 million.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% year-over-year. U.S. sales fell 16%, while international sales rose 5%. The decline was driven by a 70% drop in fluoxetine (Prozac) sales following the entry of generic competitors in August 2001.
- Profitability: Net income decreased 22% to $629.2 million. Gross margins declined 2.1 percentage points due to the lower-margin mix resulting from the Prozac decline, partially offset by growth in higher-margin products.
- Product Performance:
- Zyprexa: Sales increased 29% to $819.4 million.
- Humalog: Sales increased 42% to $177.4 million.
- Evista: Sales increased 19% to $177.9 million.
- Prozac: Sales plummeted 70% to $186.1 million.
- Expenses: Operating expenses were flat compared to Q1 2001. R&D decreased 2% due to lower late-stage trial costs, while marketing expenses increased 1% due to sales force expansion.
- Interest Expense: Decreased significantly by $31.8 million to $9.6 million due to lower interest rates on debt.
Guidance, Outlook, and Risks
Management Guidance
- Q2 2002 EPS: Expected to be in the range of $0.61 to $0.63 (excluding unusual items).
- Full Year 2002: Sales growth expected to be approximately flat. EPS expected to be $2.60 to $2.65 (excluding unusual items). Gross margins expected to decline 1.0 to 1.5 percentage points.
- 2003 Outlook: EPS growth expected to be in the teens, contingent on new product launches and FDA approvals.
Key Risks and Contingencies
- Patent Litigation: Ongoing lawsuits with Zenith Goldline and Dr. Reddy's Laboratories regarding generic versions of Zyprexa. An unfavorable outcome could materially impact operations.
- Regulatory Issues: The FDA issued a warning letter regarding Good Manufacturing Practices (cGMP) at facilities producing Zyprexa IntraMuscular and Fortéo. Resolution is required for new product approvals and could delay launches.
- Pricing Pressure: Increasing pressure from government programs (Medicare/Medicaid) and managed care organizations to reduce drug prices.
- Product Liability: Ongoing litigation regarding DES and Prozac, with accruals of approximately $134.4 million for environmental and legal liabilities.
Investor Verification Checklist
- Verify the timeline and status of FDA inspections regarding cGMP compliance for Zyprexa IntraMuscular and Fortéo.
- Monitor the progress of the Zyprexa patent litigation against Zenith and Dr. Reddy's.
- Track the sequential decline in Prozac sales and the offsetting growth rate of Zyprexa, Humalog, and Evista.
- Review the launch dates for Cialis, duloxetine, and atomoxetine, as 2003 guidance depends on these.
- Assess the impact of the $211.4 million sale of Darvon/Darvocet-N rights and the associated revenue amortization schedule.